DE60113032D1 - Glucocorticoid Rezeptor Modulatoren - Google Patents

Glucocorticoid Rezeptor Modulatoren

Info

Publication number
DE60113032D1
DE60113032D1 DE60113032T DE60113032T DE60113032D1 DE 60113032 D1 DE60113032 D1 DE 60113032D1 DE 60113032 T DE60113032 T DE 60113032T DE 60113032 T DE60113032 T DE 60113032T DE 60113032 D1 DE60113032 D1 DE 60113032D1
Authority
DE
Germany
Prior art keywords
glucocorticoid receptor
compounds
present
receptor modulators
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60113032T
Other languages
English (en)
Other versions
DE60113032T2 (de
Inventor
Kevin Kun-Chin Liu
Bradley P Morgan
Ralph Pelton Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of DE60113032D1 publication Critical patent/DE60113032D1/de
Application granted granted Critical
Publication of DE60113032T2 publication Critical patent/DE60113032T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60113032T 2000-10-30 2001-10-16 Glukokortikoidrezeptor-Modulatoren Expired - Fee Related DE60113032T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24430200P 2000-10-30 2000-10-30
US244302P 2000-10-30

Publications (2)

Publication Number Publication Date
DE60113032D1 true DE60113032D1 (de) 2005-10-06
DE60113032T2 DE60113032T2 (de) 2006-07-06

Family

ID=22922191

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60113032T Expired - Fee Related DE60113032T2 (de) 2000-10-30 2001-10-16 Glukokortikoidrezeptor-Modulatoren

Country Status (9)

Country Link
US (1) US6852719B2 (de)
EP (1) EP1201660B1 (de)
JP (1) JP2002193955A (de)
AT (1) ATE303369T1 (de)
BR (1) BR0104834A (de)
CA (1) CA2360313C (de)
DE (1) DE60113032T2 (de)
ES (1) ES2246292T3 (de)
MX (1) MXPA01011108A (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL146057A (en) * 2000-10-27 2007-09-20 Pfizer Prod Inc A process for the preparation of modulators of a non-steroidal glucocorticoid receptor
JP2006508042A (ja) * 2002-07-18 2006-03-09 ブリストル−マイヤーズ　スクイブ　カンパニー グルココルチコイド受容体の修飾物質および方法
WO2004054587A1 (en) * 2002-12-18 2004-07-01 University Of Zurich Treatment of neuro-psychiatric disorders
US7625921B2 (en) * 2004-01-16 2009-12-01 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
DK1778236T3 (da) * 2004-07-02 2010-10-25 Corcept Therapeutics Inc Modificerede pyrimidin-glucocorticoid-receptor-modulatorer
US20060154981A1 (en) * 2005-01-12 2006-07-13 Alcon, Inc. Method of reducing intraocular pressure and treating glaucoma
EP1841426B1 (de) * 2005-01-19 2011-04-27 Merck Sharp & Dohme Corp. Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer-krankheit
EP1855679B1 (de) * 2005-01-19 2016-06-29 Merck Sharp & Dohme Corp. Aminomethyl-beta-sekretase-hemmer zur behandlung von alzheimer
WO2007032556A1 (ja) 2005-09-14 2007-03-22 Santen Pharmaceutical Co., Ltd. グルココルチコイド受容体結合活性を有する新規１，２−ジヒドロキノリン誘導体
SI1995242T1 (sl) * 2006-03-14 2013-01-31 Santen Pharmaceutical Co., Ltd. Nov derivat 1,2,3,4-tetrahidrokinoksalina z aktivnostjo vezanja glukokortikoidnega receptorja
JP4898635B2 (ja) * 2006-11-14 2012-03-21 参天製薬株式会社 置換フェニルアミノ低級アルキル基とエステル構造を導入したフェニル基を置換基として有する新規１，２−ジヒドロキノリン誘導体
TWI410422B (zh) 2007-01-15 2013-10-01 Mitsubishi Tanabe Pharma Corp 縮合四氫喹啉衍生物及其醫藥用途
MX2009008284A (es) * 2007-02-02 2009-08-12 Pfizer Prod Inc Compuestos triciclicos y su uso como moduladores de receptor de glucocorticoides.
US8193187B2 (en) * 2007-05-29 2012-06-05 Santen Pharmaceutical Co., Ltd. 1,2,3,4-tetrahydroquinoxaline compound with a phenyl group substituent having a sulfonic acid ester structure or a sulfonic acid amide structure introduced therein and having glucocorticoid receptor-binding activity
CN102089283B (zh) 2008-05-12 2015-11-25 步制药股份有限公司 含有具有取代氧基的2，2，4-三甲基-6-苯基-1，2-二氢喹啉衍生物的糖皮质激素受体激动剂
MX2011001053A (es) 2008-07-28 2011-04-21 Pfizer Compuestos de fenantrenona, composiciones y metodos.
MX2011002677A (es) * 2008-09-12 2011-04-12 Santen Pharma Co Ltd Agonista del receptor de glucocorticoide que comprende nuevos derivados de 1,2,3,-4-tetrahidroquinoxalina que contienen un grupo fenilo que tiene una estructura de ester de acido sulfonico introducida en el mismo como sustituyente.
CA2742964C (en) 2008-11-07 2020-07-07 University Of Sheffield Medicament and method of diagnosis
JP2014501785A (ja) * 2011-01-07 2014-01-23 コーセプト セラピューティクス， インコーポレイテッド ステロイドおよびグルココルチコイド受容体アンタゴニスト組合せ治療
SG193509A1 (en) 2011-03-18 2013-10-30 Corcept Therapeutics Inc Pyrimidine cyclohexyl glucocorticoid receptor modulators
TW201422590A (zh) * 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
EP2935284A4 (de) 2012-12-21 2016-04-27 Abbvie Inc Heterocyclische nuklearhormonrezeptormodulatoren
CA2996278A1 (en) 2015-08-25 2017-03-02 Santen Pharmaceutical Co., Ltd. [4-(1,3,3-trimethyl-2-oxo-3,4-dihydro-1h-quinoxalin-7-yl)-phenoxy]ethyloxy compound or salt thereof
EP3768324A1 (de) 2018-03-22 2021-01-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur modulierung der angeborenen lymphoidzellaktivität, antikörper-arzneimittelkonjugate und verwendungen in der therapie
MX2020012831A (es) 2018-06-04 2021-04-28 Corcept Therapeutics Inc Moduladores del receptor de glucocorticoide de pirimidina ciclohexenilo.
CA3158745A1 (en) 2019-12-11 2021-06-17 Corcept Therapeutics Incorporated Methods of treating antipsychotic-induced weight gain with miricorilant
AU2021268944B2 (en) 2020-05-06 2024-04-18 Corcept Therapeutics Incorporated Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators
JP2024503244A (ja) 2020-12-21 2024-01-25 コーセプト セラピューティクス， インコーポレイテッド ピリミジンシクロヘキシルグルココルチコイド受容体調節因子を調製する方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3683091A (en) * 1967-11-13 1972-08-08 Wataru Nagata Certain phenanthrene compounds for treatment of acne
JPS50111098A (de) 1974-02-18 1975-09-01
FR2576025B1 (fr) 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
JPH06263688A (ja) 1991-09-04 1994-09-20 Otsuka Pharmaceut Factory Inc フェナンスレン誘導体
EP0676196A1 (de) 1993-10-13 1995-10-11 Otsuka Pharmaceutical Co., Ltd. Stickstoffmonoxid-synthese-inhibitoren
CA2149496C (en) 1994-05-19 2006-12-19 Ronald Gebhard 11,21-bisphenyl-19-norpregnane derivatives
JPH0952899A (ja) 1994-09-30 1997-02-25 Tsumura & Co ロイコトリエン拮抗剤
US5688808A (en) * 1994-12-22 1997-11-18 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US5767113A (en) * 1995-05-10 1998-06-16 The Salk Institute For Biological Studies Compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance
FR2757400B1 (fr) 1996-12-19 1999-12-17 Hoechst Marion Roussel Inc Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs
AU5729098A (en) 1996-12-24 1998-07-17 Zymogenetics Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
IL122740A (en) * 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
EP0903146A1 (de) 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (21-0H-60P) als ANitoglucocortikoid
ZA9811898B (en) 1997-12-29 2000-06-28 Ortho Mcneil Pharm Inc Anti-Inflammatory Compounds.
AU766441B2 (en) 1998-02-13 2003-10-16 Abbott Laboratories Glucocorticoid-selective anti-inflammatory agents
US6380207B2 (en) 1998-02-13 2002-04-30 Abbott Laboratories Glucocortiocoid-selective antiinflammatory agents
JP2002527355A (ja) 1998-06-08 2002-08-27 カロ バイオ アクチェブラーグ 糖尿病の治療
WO2000006137A2 (en) 1998-07-30 2000-02-10 Abbott Laboratories Glucocorticoid-selective anti-inflammatory agents
GB9816935D0 (en) 1998-08-05 1998-09-30 Karobio Ab Novel glucocortoid and thyroid receptor ligands for the treatment of metabolic disorders
NZ514465A (en) * 1999-04-30 2003-11-28 Pfizer Prod Inc Glucocorticoid receptor modulators

Also Published As

Publication number Publication date
US6852719B2 (en) 2005-02-08
CA2360313A1 (en) 2002-04-30
BR0104834A (pt) 2002-08-20
CA2360313C (en) 2006-12-05
JP2002193955A (ja) 2002-07-10
EP1201660B1 (de) 2005-08-31
US20040014741A1 (en) 2004-01-22
EP1201660A1 (de) 2002-05-02
DE60113032T2 (de) 2006-07-06
ES2246292T3 (es) 2006-02-16
MXPA01011108A (es) 2002-06-04
ATE303369T1 (de) 2005-09-15

Similar Documents

Publication Publication Date Title
DE60113032D1 (de) Glucocorticoid Rezeptor Modulatoren
ATE327974T1 (de) Modulatoren des glucocorticoid-rezeptors
AP1542A (en) Glucocorticoid receptor modulators.
ECSP034744A (es) Antagonistas de nmda/nr2b no arilo-heterociclico n-sustituidos
ATE496620T1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
DE60231341D1 (de) Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
BR0109235A (pt) Derivados do ácido carboxìlico como antagonistas ip
BRPI0509761B8 (pt) compostos de quinolinona-carboxamida como agonistas de receptor de 5-ht4, composição farmacêutica, uso dos referidos compostos e seu processo de preparação
ATE512961T1 (de) Amorphes nebivolol hydrochlorid und seine herstellung
BR0313923A (pt) Derivados de 3-(sulfonamidoetil)-indol para uso como miméticos de glicocorticóide no tratamento de doenças inflamatórias, alérgicas e proliferativas
SG165316A1 (en) Combination of a long-acting hypnotic agent and a short-acting hypnotic agent and therapeutic use of same
EA200700027A1 (ru) Антагонисты рецептора глюкагона, их получение и терапевтическое применение
ATE445609T1 (de) Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen
BR0205829A (pt) Novas aminas como ligantes dos receptores de histamina-3 e suas aplicações terapêuticas
ATE420859T1 (de) Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren
BR0115291A (pt) Derivados de 2-fenilaminoimidazolina fenil cetona substituìdos como antagonistas de ip
YU53100A (sh) Derivati 2-ariletil-(piperidin-4-ilmetil)amina kao antagonisti muskarinskih receptora
GT200000197A (es) 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6- morfolin-4-il-4-o tolil-piridin-3-il)-isobutiramida.
ATE447575T1 (de) Selektive spirocyclische glucocorticoid-rezeptor- modulatoren
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
EA200501594A1 (ru) Замещенные производные азабициклогексана в качестве антагонистов мускаринового рецептора
BR9905974A (pt) Derivados de ácido aril carboxìlico e tetrazol
ATE406363T1 (de) Methylindole und methylpyrrolopyridine als alpha- 1-adrenerge agonisten
TW200519102A (en) Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
MX2007005824A (es) Agonistas y antagonistas del receptor de somatostatina.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee